Pathogen inactivation: The definitive safeguard for the blood supply

Barbara J. Bryant, Harvey C. Klein

Research output: Contribution to journalArticle

Abstract

Context. - Pathogen inactivation provides a proactive approach to cleansing the blood supply. In the plasma fractionation and manufacturing industry, pathogen inactivation technologies have been successfully implemented resulting in no transmission of human immunodeficiency, hepatitis C, or hepatitis B viruses by US-licensed plasma derivatives since 1985. However, these technologies cannot be used to pathogen inactivate cellular blood components. Although current blood donor screening and disease testing has drastically reduced the incidence of transfusion-transmitted diseases, there still looms the threat to the blood supply of a new or reemerging pathogen. Of particular concern is the silent emergence of a new agent with a prolonged latent period in which asymptomatic infected carriers would donate and spread infection. Objective. - To review and summarize the principles, challenges, achievements, prospective technologies, and future goals of pathogen inactivation of the blood supply. Data Sources. - The current published English-language literature from 1968 through 2006 and a historical landmark article from 1943 are integrated into a review of this subject. Conclusions. - The ultimate goal of pathogen inactivation is to maximally reduce the transmission of potential pathogens without significantly compromising the therapeutic efficacy of the cellular and protein constituents of blood. This must be accomplished without introducing toxicities into the blood supply and without causing neoantigen formation and subsequent antibody production. Several promising pathogen inactivation technologies are being developed and clinically tested, and others are currently in use. Pathogen inactivation offers additional layers of protection from infectious agents that threaten the blood supply and has the potential to impact the safety of blood transfusions worldwide.

Original languageEnglish (US)
Pages (from-to)719-733
Number of pages15
JournalArchives of Pathology and Laboratory Medicine
Volume131
Issue number5
StatePublished - May 2007
Externally publishedYes

Fingerprint

Technology
Donor Selection
Infectious Disease Transmission
Hematologic Diseases
Information Storage and Retrieval
Hepatitis C
Blood Donors
Hepatitis B virus
Blood Transfusion
Antibody Formation
Blood Proteins
Language
Safety
Incidence
Infection
Therapeutics
Manufacturing Industry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Pathogen inactivation : The definitive safeguard for the blood supply. / Bryant, Barbara J.; Klein, Harvey C.

In: Archives of Pathology and Laboratory Medicine, Vol. 131, No. 5, 05.2007, p. 719-733.

Research output: Contribution to journalArticle

Bryant, Barbara J. ; Klein, Harvey C. / Pathogen inactivation : The definitive safeguard for the blood supply. In: Archives of Pathology and Laboratory Medicine. 2007 ; Vol. 131, No. 5. pp. 719-733.
@article{125ba55ed08149b0ae57d5e09a3b19b1,
title = "Pathogen inactivation: The definitive safeguard for the blood supply",
abstract = "Context. - Pathogen inactivation provides a proactive approach to cleansing the blood supply. In the plasma fractionation and manufacturing industry, pathogen inactivation technologies have been successfully implemented resulting in no transmission of human immunodeficiency, hepatitis C, or hepatitis B viruses by US-licensed plasma derivatives since 1985. However, these technologies cannot be used to pathogen inactivate cellular blood components. Although current blood donor screening and disease testing has drastically reduced the incidence of transfusion-transmitted diseases, there still looms the threat to the blood supply of a new or reemerging pathogen. Of particular concern is the silent emergence of a new agent with a prolonged latent period in which asymptomatic infected carriers would donate and spread infection. Objective. - To review and summarize the principles, challenges, achievements, prospective technologies, and future goals of pathogen inactivation of the blood supply. Data Sources. - The current published English-language literature from 1968 through 2006 and a historical landmark article from 1943 are integrated into a review of this subject. Conclusions. - The ultimate goal of pathogen inactivation is to maximally reduce the transmission of potential pathogens without significantly compromising the therapeutic efficacy of the cellular and protein constituents of blood. This must be accomplished without introducing toxicities into the blood supply and without causing neoantigen formation and subsequent antibody production. Several promising pathogen inactivation technologies are being developed and clinically tested, and others are currently in use. Pathogen inactivation offers additional layers of protection from infectious agents that threaten the blood supply and has the potential to impact the safety of blood transfusions worldwide.",
author = "Bryant, {Barbara J.} and Klein, {Harvey C.}",
year = "2007",
month = "5",
language = "English (US)",
volume = "131",
pages = "719--733",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Pathogen inactivation

T2 - The definitive safeguard for the blood supply

AU - Bryant, Barbara J.

AU - Klein, Harvey C.

PY - 2007/5

Y1 - 2007/5

N2 - Context. - Pathogen inactivation provides a proactive approach to cleansing the blood supply. In the plasma fractionation and manufacturing industry, pathogen inactivation technologies have been successfully implemented resulting in no transmission of human immunodeficiency, hepatitis C, or hepatitis B viruses by US-licensed plasma derivatives since 1985. However, these technologies cannot be used to pathogen inactivate cellular blood components. Although current blood donor screening and disease testing has drastically reduced the incidence of transfusion-transmitted diseases, there still looms the threat to the blood supply of a new or reemerging pathogen. Of particular concern is the silent emergence of a new agent with a prolonged latent period in which asymptomatic infected carriers would donate and spread infection. Objective. - To review and summarize the principles, challenges, achievements, prospective technologies, and future goals of pathogen inactivation of the blood supply. Data Sources. - The current published English-language literature from 1968 through 2006 and a historical landmark article from 1943 are integrated into a review of this subject. Conclusions. - The ultimate goal of pathogen inactivation is to maximally reduce the transmission of potential pathogens without significantly compromising the therapeutic efficacy of the cellular and protein constituents of blood. This must be accomplished without introducing toxicities into the blood supply and without causing neoantigen formation and subsequent antibody production. Several promising pathogen inactivation technologies are being developed and clinically tested, and others are currently in use. Pathogen inactivation offers additional layers of protection from infectious agents that threaten the blood supply and has the potential to impact the safety of blood transfusions worldwide.

AB - Context. - Pathogen inactivation provides a proactive approach to cleansing the blood supply. In the plasma fractionation and manufacturing industry, pathogen inactivation technologies have been successfully implemented resulting in no transmission of human immunodeficiency, hepatitis C, or hepatitis B viruses by US-licensed plasma derivatives since 1985. However, these technologies cannot be used to pathogen inactivate cellular blood components. Although current blood donor screening and disease testing has drastically reduced the incidence of transfusion-transmitted diseases, there still looms the threat to the blood supply of a new or reemerging pathogen. Of particular concern is the silent emergence of a new agent with a prolonged latent period in which asymptomatic infected carriers would donate and spread infection. Objective. - To review and summarize the principles, challenges, achievements, prospective technologies, and future goals of pathogen inactivation of the blood supply. Data Sources. - The current published English-language literature from 1968 through 2006 and a historical landmark article from 1943 are integrated into a review of this subject. Conclusions. - The ultimate goal of pathogen inactivation is to maximally reduce the transmission of potential pathogens without significantly compromising the therapeutic efficacy of the cellular and protein constituents of blood. This must be accomplished without introducing toxicities into the blood supply and without causing neoantigen formation and subsequent antibody production. Several promising pathogen inactivation technologies are being developed and clinically tested, and others are currently in use. Pathogen inactivation offers additional layers of protection from infectious agents that threaten the blood supply and has the potential to impact the safety of blood transfusions worldwide.

UR - http://www.scopus.com/inward/record.url?scp=34248145455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248145455&partnerID=8YFLogxK

M3 - Article

C2 - 17488157

AN - SCOPUS:34248145455

VL - 131

SP - 719

EP - 733

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -